Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects diagnosed of HBeAg positive or negative chronic hepatitis B~2. Aged 18 to 70 years old，male or female~3. Patients with previously HBsAg-positive, HBeAg-positive for 24 weeks, HBV-DNA\> 105copies/ml. HBeAg-negative for 24 weeks or more, HBV-DNA\> 105 copies/ml.~4. 1.3 times the upper normal limit (1.3 × ULN) ≤ alanine aminotransferase (ALT) ≤ 10 × ULN.~5. Total serum bilirubin (TBIL) ≤ 2.5 × ULN.~6. Prothrombin activity (PTA) ≥ 60% or prothrombin time prolonged than normal ≤ 3 seconds).~7. WBC ≥ 3.5 × 109 / L, PLT ≥ 70 × 109 / L, serum albumin (ALB)≥ 35 g / L.~8. Creatinine (Cr) ≤ 1.5 × ULN.~9. If patients take intermittently with interferon, nucleoside (acid) analogues, α1 thymosin before enrollment with 24 weeks, the time is no more than 12 weeks.~10. Patients signed an informed consent form and compliance was good.~Exclusion Criteria:~1. Patients were infected with other viruses as HAV, HCV, HDV, HEV, CMV, EBV, HIV etc.~2. Patients with cirrhosis or liver cancer.~3. Patients have participated in another therapeutic clinical trial in 3 months.~4. Granulocyte count \<1.5 × 109 / L, hemoglobin (HB)\<100g / L, sera alpha-fetoprotein(AFP)\> 100μg / L, patients' B ultrasonography pointed space-occupying lesions.~5. Patients with severe heart, kidney, endocrine hematopoietic system and neuropsychiatric diseases.~6. Patients with metabolic or autoimmune diseases such as systemic lupus erythematosus.~7. Pregnant woman, lactating women or those who wre allergic for study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- HBeAg positive group (Type: OTHER): Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .
- HBeAg-negative group (Type: OTHER): Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .

Based on this trial design, predict the completion outcome and termination type (if applicable).